ABBVIE

Neurocrine Biosciences announced that its ERUDITE Phase 2 study of luvadaxistat failed to meet its primary endpoint for improving cognitive impairment in schizophrenia patients, leading to the halt of further development for the compound.

FDA approves Roche's Tecentriq Hybreza™, a subcutaneous anti-PD-(L)1 immunotherapy using Halozyme's ENHANZE® technology, reducing injection time to 7 minutes from 30-60 minutes for IV infusion, available for adult indications of IV Tecentriq® in the U.S.

FDA approves Johnson & Johnson's Tremfya for ulcerative colitis, adding to its existing approvals for plaque psoriasis and psoriatic arthritis. Tremfya's potential to generate $5B in revenue is significant, especially as J&J's Stelara faces market exclusivity loss and price cuts. Competitors like AbbVie and Eli Lilly also have strong IBD treatments, intensifying the market competition.

High Adderall doses linked to fivefold increased risk of first-time psychosis or mania, especially above 40 mg.

Immunotherapy less risky for non-small cell lung cancer patients with BMI under 28, while chemotherapy is optimal for those with BMI 28 or higher, according to Osaka Metropolitan University study.

Regeneron Pharmaceuticals' PE, PB, and PS ratios are low, suggesting potential undervaluation. However, its low ROE indicates lower profitability. High EBITDA and gross profit levels indicate strong financial performance, but low revenue growth may be a concern.

Allergan Aesthetics launches BOTOX® Cosmetic for masseter muscle prominence (MMP) in China, supported by clinical trials showing effectiveness and safety. Plans include expanding MMP treatment to other global markets.

OSE Immunotherapeutics launches Artemia Phase 3 trial for Tedopi® in second-line NSCLC, targeting HLA-A2+ patients with secondary resistance to ICI, aiming for regulatory registration in Europe and North America.